Market Trends of Neuropathic Pain Industry
Diabetic Neuropathy Segment is Expected to Register a Healthy Growth Share Over the Forecast Period.
The diabetic neuropathy segment is anticipated to witness healthy growth over the forecast period. The major factors driving the growth of the segment are the increasing burden of the targeted diseases and the launch of the products for their treatment.
Sedentary and unhealthy lifestyles are major factors that contribute to the significant prevalence of diabetes around the world. For instance, according to the article regarding epidemiology and classification of diabetic neuropathy updated in January 2022, diabetic polyneuropathy is the most common neuropathy in developed countries. It also reported that approximately 50% of patients with diabetes gradually develop neuropathy. Such studies demonstrating the chances of neuropathy in diabetic patients suggest that there is a growing burden of this disease. Hence, this market segment is expected to witness growth over the forecast period.
The increasing research studies and clinical trials can also lead to the development of new products and thus may drive the growth of the segment in the future. For instance, in December 2023, Vertex Pharmaceuticals Incorporated reported encouraging outcomes from its Phase 2 trial, assessing VX-548, a selective NaV1.8 inhibitor, in individuals suffering from painful diabetic peripheral neuropathy (DPN). VX-548 showcased a notable and statistically significant reduction in the primary endpoint across all administered doses: the average weekly pain intensity, as measured on the Numeric Pain Rating Scale (NPRS), at the 12-week mark. Notably, the study featured an active reference group using pregabalin, enhancing the assessment of VX-548's efficacy.
Thus, owing to the above-mentioned factors, such as the high burden of diabetic neuropathy and rising clinical trial developments, the market segment is expected to witness growth over the forecast period.
North America is Expected to Hold a Major Share in the Neuropathic Pain Market Over the Forecast Period
North America is expected to hold a significant market share because of the high burden of neuropathic diseases, rising research and development spending, and the strong presence of market players.
As per the International Diabetes Federation (IDF) 2022 report, the number of diabetes patients in North America is projected to reach over 55 million by 2030. The rising burden of diabetes in the region is expected to attract opportunities for market growth in the area.
In addition, as per the article published by the National Institute of Health (NIH) in May 2022, the estimated R&D spending in the United States for peripheral neuropathy was USD 194 million in 2022 and USD 225 million in 2023. The grant provided by the government for research on peripheral neuropathy is expected to create opportunities for market players to develop an efficient drug that is further expected to propel market growth in the upcoming years.
Strategic initiatives such as research and development, launches, and partnerships by market players also contribute significantly to the neuropathic pain market’s growth in the region. For instance, in April 2024, Vertex Pharmaceuticals' suzetrigine, formerly known as VX-548, was making significant progress in its rolling submission for approval, which was granted by the US Food and Drug Administration (FDA) for the treatment of moderate-to-severe acute pain.
Thus, owing to factors such as high research and development and clinical trial activities, the neuropathic pain market in North America is expected to witness growth over the forecast period.
